What Does Rare Atypical Urothelial Cells Mean?

A report describing “rare atypical urothelial cells” means that a pathologist examining your urine sample spotted a small number of cells from the bladder lining that look abnormal but not clearly cancerous. In the standardized Paris System that labs use to classify urine cytology, these fall into a category called Atypical Urothelial Cells (AUC), a gray zone between obviously normal and obviously malignant. The finding is not a diagnosis of cancer, but it is not an all-clear either. Depending on the study, somewhere between roughly a third and two-thirds of people with AUC who undergo biopsy turn out to have a urothelial tumor, so the result always triggers further investigation.

What Pathologists Actually See Under the Microscope

Urine cytology works by collecting cells that shed naturally from the lining of your urinary tract and examining them under a microscope. Healthy urothelial cells have a predictable appearance: modest-sized nuclei, smooth nuclear borders, and an unremarkable ratio of nucleus to surrounding cell body. When a pathologist labels cells “atypical,” they are flagging specific deviations from that norm. The formal criteria include an increased ratio of nucleus to cytoplasm driven by the nucleus getting larger, abnormal darkness or texture of the nuclear material, and irregularity along the edge of the nucleus.

Certain microscopic features tilt the suspicion more strongly toward cancer. Cells that cluster together in papillary (finger-like) arrangements, nuclei so dark they resemble ink spots, and irregular nuclear membranes are all seen more often in samples that eventually correlate with a malignant biopsy. On the other hand, cells showing cytoplasmic vacuolization, little bubble-like spaces in the cell body, lean more toward a reactive or benign process.

The word “rare” in your report refers to cell quantity, not to how unusual the diagnosis is. It means the pathologist found only a few atypical cells on the slide rather than large numbers. This can happen because the tumor, if one exists, is small or low-shedding, or because the abnormal cells came from a benign source and there simply were not many of them. A sparse cell count does not automatically lower your risk, but it does make the pathologist’s job harder, since there is less material to evaluate.

How Often Atypical Cells Turn Out to Be Cancer

This is the question most people with an AUC result care about, and the honest answer is that published numbers vary quite a bit depending on the study population and how “risk of malignancy” is counted. A Finnish study that reviewed over 3,700 urine cytology samples found that about 5.5% fell into the AUC category. Among all AUC cases, the overall risk of malignancy was roughly 30%. When the analysis was narrowed to only those patients who actually went on to have a tissue biopsy, the rate jumped to about 63%, with about 35% specifically harboring high-grade tumors.

Those two numbers illustrate something important: the biopsy-confirmed rate is always higher because patients who get biopsied tend to be the ones with additional red flags like blood in the urine or suspicious cystoscopy findings. Patients whose workup looks completely normal are less likely to be biopsied, which pulls down the denominator. A separate study looking specifically at patients with no prior history of bladder cancer found that among the roughly one-third of AUC cases that had biopsy follow-up, about 65% came back positive for some form of malignancy.

⁴

A study from an Indian tertiary center reported an even higher correlation in voided urine samples classified as atypical: 68% had a positive biopsy, and more than half of those were high-grade cancers.

The spread across studies, from roughly 30% to 68%, reflects real differences in patient populations, referral patterns, and how aggressively follow-up biopsies were pursued. The practical takeaway is that AUC is not a finding your doctor can safely ignore. Even at the low end of that range, a one-in-three chance of malignancy warrants a thorough workup.

When Atypical Cells Are Not Cancer

Plenty of non-cancerous conditions can make urothelial cells look worrisome under the microscope. Urinary tract infections, kidney stones, and even recent catheterization or cystoscopy can inflame or irritate the bladder lining, causing cells to swell, darken, or develop irregular-looking nuclei. The bladder is an organ that encounters a lot of mechanical and chemical stress, and its cells sometimes react in ways that mimic early malignancy on a slide.

One well-documented source of false alarms is BCG therapy, a common immunotherapy instilled directly into the bladder to treat or prevent recurrence of high-grade bladder cancer. BCG triggers an intense inflammatory response, and that inflammation causes reactive changes in shed urothelial cells. Research has shown that reactive atypia and cellular degeneration from BCG are strongly associated with false-positive cytology readings.

⁵

This is a real clinical headache. A patient undergoing BCG therapy is already being monitored for bladder cancer recurrence, and their urine cytology is supposed to help detect it. But the treatment itself muddies the waters, making it harder for the pathologist to distinguish therapy-induced changes from genuine disease. If you are receiving intravesical BCG and your cytology comes back atypical, your urologist will weigh that result differently than they would for someone with no treatment history.

How Specimen Collection Affects the Result

Not all urine samples are created equal for cytology purposes. You can collect urine by simply peeing into a cup (a voided specimen) or by gathering it during a procedure like cystoscopy or catheterization (an instrumented specimen). Instrumentation adds cells by physically scraping the bladder lining, which increases the number of cells on the slide but also introduces mechanical artifact: cells that look weird because they were traumatized during collection, not because anything is wrong with them.

A study comparing the two approaches found that atypical diagnoses occurred at similar rates in both, about 7% for voided and 8% for instrumented specimens. But the story diverges on follow-up. Among patients with biopsy results, about 47% of voided-specimen AUC cases turned out to be non-benign, compared with about 33% of instrumented-specimen cases. The implication is that when atypical cells show up in a voided sample without the physical disruption of instrumentation, it may carry slightly more weight as a cancer signal.

⁶

Why Two Pathologists Might Disagree on Your Report

AUC is inherently subjective. The criteria involve judgment calls about whether a nucleus is “enlarged enough” or a nuclear border is “irregular enough” to count as atypical, and reasonable experts can land on different sides of that line. Studies evaluating how well pathologists agree with each other when classifying urine cytology under the Paris System consistently find that the AUC category has poor reproducibility. One study described agreement for AUC as “unacceptable,” even as the more clear-cut categories (negative for high-grade and positive for high-grade) showed adequate consistency.

⁷

A separate analysis confirmed this pattern: AUC and the related “suspicious for high-grade urothelial carcinoma” category both showed poor interobserver agreement, while clearly negative and clearly positive diagnoses were much more consistent.

⁸

What this means for you is that an AUC result is not a hard biological fact in the way that, say, a blood glucose number is. It is one pathologist’s interpretation of a borderline sample. If the same slides were sent to a different pathologist, you might get a different category. This does not make the result meaningless, but it does reinforce why clinicians treat it as a reason to investigate rather than as a definitive answer in itself. A second opinion on the slides is reasonable if you or your doctor want more clarity before deciding on next steps.

The Usual Workup After an Atypical Result

When urine cytology returns AUC, the standard next step is cystoscopy: a thin, flexible camera is passed through the urethra into the bladder so the urologist can visually inspect the lining for tumors, red patches, or other suspicious areas. If something abnormal is seen, a biopsy is taken during the same procedure.

Standard white-light cystoscopy misses some lesions, particularly flat tumors like carcinoma in situ that do not form obvious masses. Blue-light cystoscopy (also called photodynamic diagnosis) improves detection by using a photosensitizing agent that makes cancer cells glow under blue light. One study found that blue-light cystoscopy had a sensitivity of 93% for detecting urothelial carcinoma in situ, though its specificity was lower at 46%, meaning it also flags some spots that are not cancer.

⁹

In another study, among patients with suspicious or positive cytology but a normal-looking bladder under standard white light, blue-light flexible cystoscopy identified bladder cancer in 41% of cases. Nearly half of those cancers were visible only under the blue light and would have been missed entirely with conventional cystoscopy.

¹⁰

Because urothelial cells also line the ureters and the renal pelvis, not just the bladder, the workup typically includes imaging of the upper urinary tract. CT urography is the standard tool. Its ability to detect upper tract tumors depends heavily on the size of the lesion: one study reported a positive predictive value of 83% for large masses but 0% for small ones, with urothelial thickening falling somewhere in between at 46%. Urine cytology findings and the imaging appearance were the two strongest independent predictors of upper tract urothelial cancer.

¹¹

Molecular Tests That Help Sort Atypical Results

Because AUC sits in a diagnostic gray zone, there has been considerable interest in molecular tests that can add a second layer of information. The most studied is UroVysion FISH, a fluorescence-based test that looks for specific chromosomal abnormalities commonly seen in bladder cancer cells. In a large evaluation of over 1,800 paired urine samples, about 16% were cytologically classified as AUC. Among those, roughly 32% were clinically confirmed to have urothelial cancer. When UroVysion FISH was positive in the AUC group, 57% of those cases were confirmed to have cancer, including a high proportion of high-grade tumors.

¹²

FISH is not perfect, though. Another study examining its value specifically in AUC cases found that while cancer was diagnosed far more often in FISH-positive patients (about 49%) than FISH-negative ones (about 9%), the test had a high false-positive rate of roughly 53%. Even after extended follow-up, most of those false positives never developed cancer, arguing against the idea that FISH was simply detecting tumors before they became visible.

¹³

On the research side, newer biomarkers like urinary survivin mRNA show promise. A meta-analysis found that survivin mRNA detection had pooled sensitivity around 86% and specificity around 95% for bladder cancer, compared with conventional cytology’s sensitivity of roughly 42% at near-perfect specificity.

¹⁴

These molecular tools are useful for risk stratification, helping your urologist decide how aggressively to pursue biopsies, but none of them replace tissue biopsy as the definitive way to confirm or rule out cancer.

When the Entire Workup Comes Back Normal

This is one of the most anxiety-producing scenarios: your cytology says atypical, but the cystoscopy looks clean and the imaging shows nothing. What then?

Research on this question offers some reassurance. A study tracking patients with suspicious or atypical cytology whose initial cystoscopy and imaging were negative found that the patients who eventually developed urothelial tumors either had persistent atypical or suspicious cells on repeat urine tests or had recurrent episodes of blood in the urine. The average time for a lesion to show up in those patients was about 5.6 months, with a range of 3 to 12 months. Persistent abnormal cells on repeat cytology was the only factor that significantly predicted later tumor development.

¹⁵

Another study went further and concluded that in patients whose cystoscopy and urography both showed no evidence of urothelial malignancy, atypical cytology alone did not predict later development of a tumor. The authors argued that these patients did not require prolonged follow-up, repeated cytology testing, or additional imaging beyond the initial negative workup.

¹⁶

These two studies are not contradictory: they converge on the same practical point. The key variable is what happens on repeat testing. If your follow-up cytology normalizes and your symptoms resolve, the initial atypical result was most likely driven by a benign process. If atypical cells keep appearing, that persistence is the signal to keep looking.

Practical Advice for Navigating an AUC Report

If you are reading your cytology report and it says something like “rare atypical urothelial cells” or “atypical urothelial cells, cannot exclude malignancy,” here are the things worth knowing as you head into conversations with your urologist:

It is not cancer: AUC is a flag for further evaluation, not a diagnosis. Many people with this finding turn out to have inflammation, infection, or nothing at all.
It is not nothing: The malignancy rates across multiple studies are high enough that skipping follow-up would be unwise. Expect to have a cystoscopy and likely some form of upper-tract imaging.
Context matters enormously: Your age, smoking history, presence of blood in the urine, prior cancer history, and recent procedures all change how your urologist interprets the result. A 35-year-old with a recent UTI and an AUC reading is in a very different risk category than a 70-year-old smoker with visible blood in the urine.
One atypical result followed by a clean workup is usually the end: If cystoscopy and imaging are both normal and a repeat urine test comes back clean, ongoing surveillance for that isolated finding is generally not needed.
Persistent atypia is the real red flag: If repeat cytology keeps showing atypical cells, that is the finding that most strongly predicts an eventual cancer diagnosis, even if the bladder looks normal on camera.

Why This Category Exists at All

It is fair to wonder why pathology labs do not simply report cells as either normal or cancerous and skip the ambiguity. The reality is that urine cytology is very good at detecting high-grade bladder cancer, where the cells look dramatically abnormal, but it struggles with low-grade tumors and early-stage disease. Low-grade urothelial cancer cells often look almost normal, with only subtle changes in nuclear size or texture. The AUC category exists precisely to capture these borderline cases rather than forcing them into a binary that would either miss cancers by calling them normal or alarm patients by calling them malignant when they may not be.

The Paris System, introduced in 2016 and updated since, was designed to standardize how labs report urine cytology and to make the categories more clinically actionable. Its emphasis is on catching high-grade disease, which is the type most likely to progress and threaten life. The tradeoff is that low-grade tumors and equivocal findings get lumped into categories like AUC, where the follow-up recommendation is the same regardless of exactly how atypical the cells look: investigate with cystoscopy and imaging, and let the tissue biopsy give you the definitive answer.

For a patient holding a report that uses this terminology, the most useful thing to understand is that your pathologist is being honest about uncertainty rather than papering over it. The cells did not look right, but they did not look clearly malignant either. The label is a professional way of saying “I cannot tell from this slide alone; you need a closer look.” That closer look, usually cystoscopy, is what turns the ambiguity into an answer.